Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Helicobacter Pylori Immunoassays Evaluated for Efficacy

By LabMedica International staff writers
Posted on 19 Mar 2018
Helicobacter pylori are curved gram negative bacilli and have been etiologically associated with several pathogenic conditions of the stomach ranging from gastritis to gastric cancer. More...
Prevalence of H. pylori infection varies based on several factors globally and in developing countries more than 80% of the population is infected with H. pylori.

Helicobacter pylori antibody titers fall very slowly even after successful treatment. Therefore, tests detecting H. pylori antibody lack specificity and sensitivity. On the other hand, H. pylori stool antigen tests are reported as an alternative assay because of their reliability and simplicity. Serology is a widely available and inexpensive test but with low diagnostic accuracy. On the other hand, the H. pylori stool antigen (HpSA) test has been put in the market as optional technique because of its reliability and simplicity.

Medical scientists at the University of Gondar (Gondar, Ethiopia) conducted a cross sectional study on patients with dyspepsia from February to March 2015 attending the medical outpatient department of the University Hospital. Stool and blood specimens were collected from each patient for serologic tests. The blood was centrifuged until serum was separated and stored at –20 °C. The stool specimens were also stored at –20 °C until the laboratory tests were performed.

A total of 201 dyspeptic patients were included in the study of which 140 (69.7%) were males and 60 (30.3%) were females. The age of the participants ranged from 7 to 85 years with a mean age of 29.5 ±14.85 years. The team evaluated the performance of SD BIOLINE H. pylori Ag rapid test with reference to the commercially available SD BIOLINE H. pylori Ag ELISA and the EZ- STEP ELISA tests. The dBest H. pylori Test Disk was also evaluated.

The team found that 75 (37.1%) of the participants were positive by the SD BIOLINE H. pylori Ag rapid test, while 92 (45.8%) were positive by the SD H. pylori Ag ELISA. The EZ-STEP H. pylori Ag ELISA detected 81 (40.3%) of the samples as positives for H. pylori infection. On the other hand, 68 (33.8%) were positive using both ELISA tests. The dBest H. pylori Test disk detected 143(71.1%) of the samples as positive. The sensitivity, specificity, positive and negative predictive values of the SD BIOLINE H. pylori Ag rapid test were: 95.6%, 92.5%, 86.7%, and 97.6%, respectively.

The authors concluded that The SD BIOLINE H. pylori Ag rapid test has a much better sensitivity, specificity and predictive values compared to the currently available antibody test in the market, in Ethiopia. Therefore, the SD BIOLINE H. pylori Ag rapid stool test could be used to diagnose active H. pylori infection before the commencement of eradication therapy. The study was published on March 5, 2018, in the journal BMC Clinical Pathology.

Related Links:
University of Gondar


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.